6340 Quadrangle Drive
United States - Map
Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics to treat drug-resistant bacterial infections in the community and hospital. The company develops solithromycin in oral and intravenous formulations for the treatment of respiratory tract infections, including community acquired bacterial pneumonia (CABP) and bacterial urethritis comprising gonorrhea. Its solithromycin product candidate is in Phase III clinical trial for the treatment of CABP. The company also develops Taksta, an oral therapy for the long term treatment of prosthetic joint infections caused by staphylococci. Its Taksta product candidate has completed a Phase II clinical trial in patients with acute bacterial skin and skin structure infections; and is in Phase II clinical trial for the treatment of prosthetic joint infections. In addition, the company intends to use its series of proprietary lead compounds for the treatment of chronic inflammatory diseases, endocrine diseases, and gastric motility disorders. Cempra, Inc. has collaborative research and development, and license agreement with Optimer Pharmaceuticals, Inc. The company was formerly known as Cempra Holdings, LLC and changed its name to Cempra, Inc. in February 2012. Cempra, Inc. was founded in 2005 and is headquartered in Chapel Hill, North Carolina.
|Cempra, Inc.’s ISS Governance QuickScore as of Nov 1, 2013 is 6. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 5; Compensation: 7.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Prabhavathi B. Fernandes Ph.D.,
Founder, Chief Exec. Officer, Pres and Director
|Mr. Mark W. Hahn ,
Chief Financial Officer, Principal Accounting Officer and Exec. VP
|Ms. E. Cali Downs Ph.D.,
Director of Operations
|Mr. Kenneth Eheman Jr.,
|Mr. Carl T. Foster ,
Exec. VP of Bus. Devel.
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|